ESR1 and cancer: Prior clinical research suggests a fulvestrant dose response (14, 15), and patients were treated with extended-dose fulvestrant (500 mg) given every 2 weeks, twice as frequently as standard dosing, to increase fulvestrant exposure and target ESR1 mutant cancers.